APA (7th ed.) Citation

DG, W., DP, W., KM, Y., SC, R., S, J., JK, M., . . . BN, R. (2006). Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: Synthesis and structure--activity relationship. Journal of medicinal chemistry, 49(14), 4425. https://doi.org/10.1021/jm0602413

Chicago Style (17th ed.) Citation

DG, Wishka, et al. "Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the Alpha7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure--activity Relationship." Journal of Medicinal Chemistry 49, no. 14 (2006): 4425. https://doi.org/10.1021/jm0602413.

MLA (9th ed.) Citation

DG, Wishka, et al. "Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an Agonist of the Alpha7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia: Synthesis and Structure--activity Relationship." Journal of Medicinal Chemistry, vol. 49, no. 14, 2006, p. 4425, https://doi.org/10.1021/jm0602413.